RISK FOR LOW VISUAL ACUITY AFTER 1 AND 2 YEARS OF TREATMENT WITH RANIBIZUMAB OR BEVACIZUMAB FOR PATIENTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION
PURPOSE:: To investigate how patients with neovascular age-related macular degeneration treated with ranibizumab or bevacizumab respond to treatment in daily clinical practice. METHODS:: Data from the Swedish Macula Register on the treatment received by 3,912 patients during 2011 to 2014 is reported. Patientsʼ characteristics at the first visit, visual acuity, number of injections, and reason for